Address the scarcity of epidemiologic, clinical, genomic/biomarker, economic, patient reported outcome, and humanistic data on the treatment path of prostate cancer including all stages of the disease. Leverage real-life data on patients from different European countries, using existing registries, trial data, and data from prostate cancer specialized centres as well as data from patient groups. Foster the collection and use of data to improve the outcomes and health system efficiency, an aim of the entire BD4BO.
Prostate cancer (PCa) is the second most common cancer in men.
Most recent clinical research focuses on the late stages of PCa, but there is a lack of data to support clinical practice in the early stages. While prognostic factors linked with overall survival have been proposed, there is no clear treatment path according to these factors. Despite a large increase in new technologies, there is also scarce data on whether real world outcomes of patients are improving.
- Identifying relevant outcomes to assess the impact of Prostate Cancer on patients’ lives
- Identifying and building real-world data sets that are suitable for answering questions about the natural history, cost-effectiveness, and clinical utility of new and innovative diagnostic and treatment interventions across the disease;
- Engagement with stakeholders to ensure future prospective data collection efforts
- Providing a road map of aligned outcomes to enable healthcare systems to adopt precision medicine